Landscape Capital Management L.L.C. Raises Holdings in CVS Health Corporation $CVS

Landscape Capital Management L.L.C. increased its position in CVS Health Corporation (NYSE:CVS) by 31.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 109,755 shares of the pharmacy operator’s stock after acquiring an additional 26,402 shares during the quarter. Landscape Capital Management L.L.C.’s holdings in CVS Health were worth $8,274,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of CVS Health by 1.7% in the second quarter. Vanguard Group Inc. now owns 120,399,131 shares of the pharmacy operator’s stock worth $8,305,132,000 after purchasing an additional 2,063,737 shares in the last quarter. Capital World Investors lifted its stake in shares of CVS Health by 2.1% during the 3rd quarter. Capital World Investors now owns 68,382,158 shares of the pharmacy operator’s stock valued at $5,155,380,000 after buying an additional 1,419,575 shares in the last quarter. State Street Corp lifted its stake in shares of CVS Health by 1.4% during the 2nd quarter. State Street Corp now owns 58,788,585 shares of the pharmacy operator’s stock valued at $4,055,237,000 after buying an additional 800,414 shares in the last quarter. Geode Capital Management LLC boosted its holdings in CVS Health by 2.4% in the 2nd quarter. Geode Capital Management LLC now owns 28,635,233 shares of the pharmacy operator’s stock worth $1,966,083,000 after buying an additional 675,824 shares during the period. Finally, Capital International Investors grew its stake in CVS Health by 1.1% in the 3rd quarter. Capital International Investors now owns 26,692,203 shares of the pharmacy operator’s stock valued at $2,012,347,000 after buying an additional 302,499 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on CVS shares. Barclays increased their target price on CVS Health from $87.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of CVS Health in a research note on Monday, December 29th. Robert W. Baird increased their price objective on CVS Health from $82.00 to $92.00 and gave the stock an “outperform” rating in a report on Wednesday, December 10th. Morgan Stanley lifted their target price on CVS Health from $89.00 to $93.00 and gave the company an “overweight” rating in a report on Wednesday, December 10th. Finally, UBS Group restated an “outperform” rating on shares of CVS Health in a research report on Wednesday, December 10th. Twenty research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $95.05.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Sanford C. Bernstein upgraded CVS to “outperform” and raised its price target (cited in market coverage), signaling analyst confidence that could support further upside. Occidental Petroleum, CVS, Petco: Top Analyst Calls
• Positive Sentiment: CVS announced an AI-powered health platform rollout, pointing to digital/service-led revenue expansion and potential margin benefits over time if adoption scales. CVS to launch new AI-powered health platform
• Positive Sentiment: CVS joined an international movement to become menopause-accredited, expanding clinical services in retail/clinic channels — a small but constructive example of diversifying care offerings. CVS Health joins international movement to become menopause accredited
• Neutral Sentiment: Analysts are updating valuations: one fair-value update nudged CVS’s estimate slightly higher (~$96.38), reflecting optimism on Medicare Advantage but continued debate on managed-care earnings and capital allocation. How The CVS Health (CVS) Story Is Shifting With Medicare Advantage And Valuation Debates
• Neutral Sentiment: Comparison pieces and retirement-portfolio coverage (CVS vs. Cigna) highlight CVS’s diversified model (retail, PBM, insurance) — useful context for longer-term investors but not an immediate catalyst. CVS vs Cigna: Which Healthcare Giant Belongs in Your Retirement Portfolio?
• Negative Sentiment: Aetna, a CVS unit, agreed to pay $117.7M to resolve DOJ False Claims Act allegations over Medicare Advantage coding — a meaningful compliance cost and a reminder of regulatory/legal risk for managed-care operations. CVS Health’s Aetna to Pay $117.7 Million to Resolve False Claims Act Allegations
• Negative Sentiment: CVS warned it may close 100+ Tennessee pharmacies over proposed PBM legislation — a potential near-term hit to retail revenues, local access and political/regulatory uncertainty in pharmacy operations. CVS threatens to close 100+ Tennessee pharmacies over PBM legislation

CVS Health Price Performance

Shares of NYSE:CVS traded up $0.81 during trading on Friday, reaching $76.88. The company had a trading volume of 477,079 shares, compared to its average volume of 9,004,375. The company has a fifty day moving average of $78.25 and a two-hundred day moving average of $77.71. The company has a current ratio of 0.84, a quick ratio of 0.63 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $97.81 billion, a P/E ratio of 55.68, a price-to-earnings-growth ratio of 0.79 and a beta of 0.49. CVS Health Corporation has a 12 month low of $58.35 and a 12 month high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Tuesday, February 10th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The company had revenue of $105.69 billion during the quarter, compared to the consensus estimate of $103.67 billion. During the same period in the previous year, the firm posted $1.19 EPS. The firm’s revenue was up 8.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Equities research analysts forecast that CVS Health Corporation will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 22nd. This represents a $2.66 annualized dividend and a dividend yield of 3.5%. CVS Health’s dividend payout ratio (DPR) is 192.75%.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.